Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : Politics for Pros- moderated -- Ignore unavailable to you. Want to Upgrade?

To: aladin who wrote (96740)	1/25/2005 2:28:23 PM
From: Ilaine	Respond to of 793698

The statistical support for BiDil is questionable. ncbi.nlm.nih.gov ncbi.nlm.nih.gov ncbi.nlm.nih.gov ncbi.nlm.nih.gov It is true that genetic variations may be more common in persons from certain geographic areas, e.g., there is a gene (CCR5 Delta 32) which gives resistance to HIV infection which is more common among people with European origins than people with African or Asian origins. But the real difference is at the gene level, not the geographcal level, nor the skin color level. cdc.gov

To: aladin who wrote (96740)	1/26/2005 8:21:56 AM
From: Mary Cluney	Read Replies (1) \| Respond to of 793698

NitroMed Submits BiDil New Drug Application Amendment; Company Prepares for Commercialization of First Heart Failure Treatment for African Americans IMO this has no significance whatsoever. It is one pharmaceutical company trying to salvage their investment in a product from extinction by using some clever marketing ploy. It has no moree significance than any marketing outfit trying to market their product to a particular niche whether they be rich, poor, tall, short, beautifu, ugly, smart, dumb, young, old, etc., etc.